Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

Steady Progress BioNxt’s approach starts with a practical problem: some patients have difficulty swallowing tablets. The Canadian company is therefore developing, among other things, thin films ...

Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...

While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with ...

BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer. The setback raises questions about the mRNA vaccine's prospects in treating pancreatic cancer. However, it's ...

BioNTech's pipeline setback shouldn't have completely surprised investors. The independent Data Safety Monitoring Board (DSMB) for the Phase 2 study of autogene cevumeran concluded in October 2025 ...

Let's start with BioNTech's recent announcement of Phase 2 clinical trial results for autogene cevumeran, an mRNA-based personalized cancer vaccine for certain patients with colorectal cancer. The ...

New details have emerged about an initiative that starts in December to fast-track the vaccines, similar to the successful ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly ...